

# 1 **The relationship between anxiety and levels of Alzheimer's disease plasma biomarkers**

2 Mark A. Bernard<sup>1,2</sup>, Allal Boutajangout<sup>1,2</sup>, Ludovic Debure<sup>1,2</sup>, Wajjha Ahmed<sup>1,2</sup>, Anthony Q.  
3 Briggs<sup>1,2</sup>, Carolina Boza-Calvo<sup>2,3,4</sup>, Alok Vedvyas<sup>1,2</sup>, Karyn Marsh<sup>1,2</sup>, Omonigho M. Bubu<sup>1,2,5</sup>,  
4 Ricardo S. Osorio<sup>2,5</sup>, Thomas Wisniewski<sup>1,2</sup>, Arjun V. Masurkar<sup>1,2,6</sup>

5  
6 <sup>1</sup>Center for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine,  
7 New York, NY

8 <sup>2</sup>Alzheimer's Disease Research Center, NYU Grossman School of Medicine, New York, NY

9 <sup>3</sup>Centro de Investigación en Hematología y Trastornos Afines (CIHATA), Universidad de Costa  
10 Rica, San José, Costa Rica

11 <sup>4</sup>Escuela de Medicina, Universidad de Costa Rica, San José, Costa Rica

12 <sup>5</sup>Department of Psychiatry, NYU Grossman School of Medicine, New York, NY

13 <sup>6</sup>Neuroscience Institute, NYU Grossman School of Medicine, New York, NY

14  
15 Corresponding author:

16 Mark A. Bernard, PhD

17 [mark.bernard@nyulangone.org](mailto:mark.bernard@nyulangone.org)

## 18 19 **ABSTRACT**

20 Anxiety is highly prevalent in Alzheimer's disease (AD), correlating with CSF/PET biomarkers and  
21 disease progression. Relationships to plasma biomarkers are unclear. Herein, we compare levels  
22 of plasma biomarkers in research participants with and without anxiety at cognitively normal, mild  
23 cognitive impairment, and AD dementia stages. We observed significantly higher plasma  
24 tau/A $\beta$ 42 ratio in AD participants with anxiety versus those without, but did not observe differences  
25 at other stages or plasma biomarkers. No such relationships were evident with depression. These  
26 results support a unique pathophysiological relationship between anxiety and AD that can be  
27 reflected in plasma biomarkers, suggestive of heightened neurodegeneration.

28 Keywords: Alzheimer's Disease, Biomarkers, Anxiety, Plasma, Dementia

29

30

## 31 INTRODUCTION

32 Neuropsychiatric symptoms (NPS) are common in Alzheimer's disease (AD) and AD-related  
33 dementias (ADRD) [1, 2]. In particular, anxiety is highly prevalent in individuals with AD even at  
34 early stages, varying between 10-49% among those with subjective cognitive decline, and 10-  
35 70% in individuals with mild cognitive impairment (MCI), and is associated with faster disease  
36 progression [3].

37 This relationship between anxiety and AD is also seen at the biomarker level, including structural  
38 magnetic resonance (MRI), F-fluorodeoxyglucose positron emission tomography (FDG-PET), and  
39 amyloid/tau measured via cerebrospinal fluid and PET [3]. However, the correlation of anxiety to  
40 plasma AD biomarkers is unclear. Plasma biomarkers confer several potential advantages for  
41 evaluating AD pathogenesis. There is evidence that changes in plasma biomarkers may preview  
42 changes in CSF or PET biomarkers, thus potentially enabling earlier insight into the relationship  
43 of anxiety with disease progression at early stages. In addition, assessment of proteinopathy in  
44 the periphery can offer a more in-depth investigation into dynamics leading to amyloid/tau  
45 deposition in the brain [4, 5]. From a practical perspective, if anxiety is to be utilized as a prescreen  
46 for further biomarker investigation in vulnerable populations, plasma biomarkers offer a more cost-  
47 effective and less invasive means to assess AD risk at a biological level.

48 In this study, we performed a cross-sectional analysis on a research cohort of older adults to test  
49 the hypothesis that plasma AD biomarker levels differ between anxious and non-anxious  
50 participants across the AD spectrum. We leveraged SIMOA technology to acquire high-fidelity  
51 measurements of plasma A $\beta$ 42, A $\beta$ 40, NfL, and total tau. Additionally, we assessed whether  
52 potential differences in plasma AD biomarker relationships were unique to anxiety by also  
53 investigating their correlations to depression.

## 54 MATERIALS AND METHODS

### 55 *Study participants*

56 A cross-sectional analysis was performed on a deidentified dataset of participants evaluated at  
57 the NYU Alzheimer's Disease Research Center (ADRC) between 2006 and 2019. The NYU  
58 ADRC study is approved by the New York University Grossman School of Medicine Institutional  
59 Review Board. Participants were community-dwelling older adults living in the greater New York  
60 City metropolitan area, recruited through community events and physician- or self-referrals. NYU  
61 ADRC inclusion criteria were age > 50, a study partner, fluency of participant and study partner

62 in English or Spanish, and willingness to undergo phlebotomy and MRI. Exclusion criteria included  
63 significant non-AD/ADRD neurological disease, HIV/AIDS, organ transplantation, organ failure,  
64 significant autoimmune disease, significant psychiatric disease, malignancy within the last 5  
65 years, and alcohol/drug abuse. The present study includes participants whose study partners  
66 gave responses to questions for anxiety and depression on the NPI-Q, and who had data for at  
67 least one AD plasma biomarker measured (n = 197).

### 68 *Clinical measurements*

69 Participants underwent clinical interviews, physical examinations, and were administered  
70 psychometric testing and other instruments according to the National Alzheimer's Coordinating  
71 Center (NACC) Uniform Data Set, in addition to NYU-specific assessments. These data were  
72 synthesized into a consensus diagnosis by ADRC Clinical Core clinicians to determine AD stage  
73 (e.g. cognitively normal, MCI, mild AD dementia). Neuropsychiatric symptoms were assessed by  
74 study partner report via the Neuropsychiatric Inventory Questionnaire (NPI-Q) for anxiety,  
75 depression, and other symptoms [6]. Participants were considered anxious or depressed if study  
76 partners answered affirmatively to the respective NPI-Q items. Blood was also collected and  
77 stored for evaluation of APOE genotype and measurement of AD plasma biomarkers.

### 78 *Measurement of blood plasma biomarkers*

79 Blood samples were collected in 10 mL EDTA tubes, gently inverted, and centrifuged at 3000 rpm  
80 for 15 minutes at room temperature. The plasma was extracted into propylene low-binding tubes,  
81 which were promptly stored at -80° C. Plasma samples were centrifuged 10.000 g for 5 minutes  
82 before use. Plasma biomarker levels of A $\beta$ 42, A $\beta$ 40, total tau, and NfL were measured using a  
83 Quanterix Single Molecule Array (SIMOA) HD-1 Analyzer and related kits. Assays were  
84 performed in duplicate using two internal standards and calibrated with an 8-point calibration  
85 curve.

### 86 *Statistical Analysis*

87 Statistical analysis was performed with GraphPad Prism. Chi-squared tests were used to compare  
88 categorical and demographic data between groups. Unpaired t-tests were performed to compare  
89 means of continuous variables (measured plasma biomarker levels) between anxious and non-  
90 anxious groups of participants. Similar analyses were conducted in participants with depression.

## 91 RESULTS

92 Demographic and genetic data for the 197 participants are summarized in Table 1. Of 197  
93 participants, 103 were cognitively normal (CN), 53 were at mild cognitive impairment (MCI), and  
94 41 were at the AD stage. Anxiety had a prevalence of 14%, 48%, and 24% at CN, MCI, and AD  
95 stages, respectively among this cohort. There were no statistically significant differences among  
96 anxious and non-anxious groups within a particular stage, nor between stages among  
97 anxious/non-anxious groups (Table 2).

98 We compared the levels of each plasma biomarker ( $A\beta_{40}$ ,  $A\beta_{42}$ , NfL, tau) and relevant ratios  
99 ( $A\beta_{42}/40$ , tau/ $A\beta_{42}$ ) between anxious and non-anxious participants across each AD stage. The  
100 tau/ $A\beta_{42}$  ratio was the only measure to show statistically significant findings (Figure 1A), with  
101 plasma tau/ $A\beta_{42}$  ratios elevated by 66% between anxious and non-anxious participants at the  
102 AD stage ( $p = 0.0127$ ).

103 In comparison to anxiety, depression had a higher prevalence of 37% at the AD stage in our  
104 cohort. Despite this increased prevalence, however, we did not observe a significant difference in  
105 tau/ $A\beta_{42}$  ratio associated with depression at any stage (Figure 1B). Depression was also not  
106 associated with stage-specific differences in  $A\beta_{40}$ ,  $A\beta_{42}$ ,  $A\beta_{42}/40$ , NfL, or tau (data not shown).

107 Lastly, we evaluated whether the higher tau/ $A\beta_{42}$  in the anxious AD group was associated with  
108 worsened cognitive performance (Table 2). Comparing psychometric performance on global  
109 (Mini-Mental State Examination) and domain-specific (animal and vegetable fluency, Trails A)  
110 tests, there was no significant difference between anxious and non-anxious AD groups.

## 111 DISCUSSION

112 Our finding that plasma tau/ $A\beta_{42}$  was significantly elevated in anxious AD subjects is consistent  
113 with previous findings in CSF. In one longitudinal study of CN individuals, higher CSF tau/ $A\beta_{42}$   
114 levels predicted a higher degree of anxiety and other NPS at 2-year follow-up [7]. In a prior cross-  
115 sectional study, it was observed that anxiety was significantly associated with lower levels of CSF  
116  $A\beta_{42}$  and higher levels of t-tau, findings consistent with a larger tau/ $A\beta_{42}$  ratio [8]. Similarly to  
117 our findings, these results were not replicated in participants with depression.

118 Higher total tau levels are known to correlate with increased neurodegeneration [9], thus one  
119 interpretation of elevated tau/ $A\beta_{42}$  ratio is a greater degree of neurodegeneration at a given level  
120 of amyloidosis. This suggests that neurodegeneration takes place more quickly at a given disease  
121 stage for individuals with anxiety, and associates with a higher level of decline. Broadly, this is in

122 agreement with previous literature. In one 3-year longitudinal study, among participants with MCI,  
123 the presence of anxiety led to an almost 2-fold increase in conversion to AD compared to non-  
124 anxious participants, and 30-fold in comparison to cognitively normal non-anxious participants  
125 [10]. Subsequent longitudinal studies have further confirmed these findings, with one study of  
126 812 ADNI participants demonstrating NPI-Q reported anxiety at baseline significantly predicted  
127 MCI to AD conversion [11], and another study of 376 amnesic MCI participants observing  
128 significantly increased conversion to AD in anxious participants (with conversion increasing in line  
129 with anxiety severity) [12].

130 We have observed that this effect appears to be specific to anxiety, as our findings were not  
131 duplicated in participants with depression. This may suggest a pathophysiological mechanism or  
132 biomarker signature that is specific for anxiety. Alternatively, a recent review summarizes the  
133 evidence in the literature that depression in AD, in contrast to anxiety, may potentially arise more  
134 from psychosocial factors surrounding the disease, rather than a physiological mechanism [13].  
135 Interestingly, we found that cognitive testing did not significantly differ between anxious and non-  
136 anxious AD participants, despite the significant difference in plasma tau/A $\beta$ 42. This finding adds  
137 further support to the theory that AD-related anxiety may not, in fact, be solely a psychosomatic  
138 response to the knowledge of cognitive decline, but instead perhaps has some heretofore  
139 undescribed physiological mechanism that is observable via biomarkers. Another possibility is  
140 that the rate of decline from the MCI stage to AD is increased in participants with anxiety [14],  
141 such that similar cognitive performance is reached over a shorter period of time.

142 Strengths of our study include a robustly phenotyped cohort, consensus diagnoses, and  
143 evaluation of plasma biomarkers via an ultrasensitive protein detection method. However, there  
144 are a few limitations. The cohort was modest in size and largely non-Hispanic White. The latter  
145 may lessen generalizability as NPS can have unique manifestations in different populations and  
146 associations with biomarker levels[15]. Further, our study evaluated NPS via the he NPI-Q, which  
147 is partner-based, and may differ from participant-based assessments.

148 In summary, this work demonstrates that anxiety is associated with unique plasma biomarker  
149 levels in AD, potentially related to increased neurodegeneration. This supports longitudinal  
150 investigation on the association of anxiety with biomarker changes and further study of the  
151 pathophysiologic relationship between anxiety and AD.

## 152 **ACKNOWLEDGMENTS**

153 The authors have no acknowledgments to report

154 **FUNDING**

155 This work was supported by NIH P30AG066512 and the Louis J. And June E. Kay Foundation.

156 OMB additionally receives funding support from NIA (L30AG064670, K23AG068534,  
157 R01AG082278, RF1AG083975), Alzheimer’s Association (AARG-D-21-848397), American  
158 Academy of Sleep Medicine (AASM-231-BS-20), and BrightFocus Foundation (BrightFocus-  
159 ADR-22-924755), TW receives additional funding from NIA P01AG060882. AQB receives  
160 additional funding from Alzheimer’s Association (AARF-D-24-1243696).

161 **CONFLICT OF INTEREST**

162 Arjun V. Masurkar is on the council for the Alzheimer’s Association International Research Grants  
163 Program and the steering committee for the Alzheimer Disease Cooperative Study, both unpaid  
164 positions. All other authors have no conflict of interest to report.

165 **DATA AVAILABILITY**

166 The data supporting the findings of this study are available upon request from the corresponding  
167 author. The data are not publicly available due to privacy or ethical restrictions.

168

169

170 **REFERENCES**

- 171
- 172 [1] Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N (1997) Behavioral and  
173 Psychological Signs and Symptoms of Dementia: A Consensus Statement on Current  
174 Knowledge and Implications for Research and Treatment. *International Psychogeriatrics*  
175 **8**, 497-500.
- 176 [2] Spalletta G, Musicco M, Padovani A, Perri R, Fadda L, Canonico V, Trequattrini A,  
177 Pettenati C, Caltagirone C, Palmer K, Rozzini L (2010) Neuropsychiatric Symptoms and  
178 Syndromes in a Large Cohort of Newly Diagnosed, Untreated Patients With Alzheimer  
179 Disease. *The American Journal of Geriatric Psychiatry* **18**, 1026-1035.
- 180 [3] Patel P, Masurkar AV (2021) The Relationship of Anxiety with Alzheimer's Disease: A  
181 Narrative Review. *Current Alzheimer Research* **18**, 359-371.
- 182 [4] Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M,  
183 Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman  
184 RJ (2017) Amyloid  $\beta$  concentrations and stable isotope labeling kinetics of human plasma  
185 specific to central nervous system amyloidosis. *Alzheimer's & Dementia* **13**, 841-849.
- 186 [5] Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li Q-X,  
187 Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K,  
188 Tanaka K, Masters CL, Yanagisawa K (2018) High performance plasma amyloid- $\beta$   
189 biomarkers for Alzheimer's disease. *Nature* **554**, 249-254.
- 190 [6] Daniel I. Kaufer, M.D. , Jeffrey L. Cummings, M.D. , Patrick Ketchel, M.Ed. , Vanessa  
191 Smith, Audrey MacMillan, C.R.N.P. , Timothy Shelley, M.S.W. , Oscar L. Lopez, M.D. ,  
192 and, Steven T. DeKosky, M.D. (2000) Validation of the NPI-Q, a Brief Clinical Form of the  
193 Neuropsychiatric Inventory. *The Journal of Neuropsychiatry and Clinical Neurosciences*  
194 **12**, 233-239.
- 195 [7] Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TLS, Fagan AM,  
196 Morris JC, Roe CM (2016) Mood Changes in Cognitively Normal Older Adults are Linked  
197 to Alzheimer Disease Biomarker Levels. *The American Journal of Geriatric Psychiatry* **24**,  
198 1095-1104.
- 199 [8] Banning LCP, Ramakers IHGB, Köhler S, Bron EE, Verhey FRJ, de Deyn PP, Claassen  
200 JAHR, Koek HL, Middelkoop HAM, van der Flier WM, van der Lugt A, Aalten P (2020) The  
201 Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's  
202 Disease Spectrum. *The American Journal of Geriatric Psychiatry* **28**, 735-744.

- 203 [9] Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, Hölttä M, Rosén C,  
204 Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H (2016) CSF and  
205 blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-  
206 analysis. *The Lancet Neurology* **15**, 673-684.
- 207 [10] Palmer K, Berger AK, Monastero R, Winblad B, Bäckman L, Fratiglioni L (2007) Predictors  
208 of progression from mild cognitive impairment to Alzheimer disease. *Neurology* **68**, 1596-  
209 1602.
- 210 [11] Wadsworth LP, Lorius N, Donovan NJ, Locascio JJ, Rentz DM, Johnson KA, Sperling RA,  
211 Marshall GA (2012) Neuropsychiatric Symptoms and Global Functional Impairment along  
212 the Alzheimer's Continuum. *Dementia and Geriatric Cognitive Disorders* **34**, 96-111.
- 213 [12] Mah L, Binns MA, Steffens DC (2015) Anxiety Symptoms in Amnesic Mild Cognitive  
214 Impairment Are Associated with Medial Temporal Atrophy and Predict Conversion to  
215 Alzheimer Disease. *The American Journal of Geriatric Psychiatry* **23**, 466-476.
- 216 [13] Banning LCP, Ramakers IHGB, Deckers K, Verhey FRJ, Aalten P (2019) Affective  
217 symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer's disease:  
218 A systematic literature review. *Neuroscience & Biobehavioral Reviews* **107**, 346-359.
- 219 [14] Devier DJ, Pelton GH, Tabert MH, Liu X, Cuasay K, Eisenstadt R, Marder K, Stern Y,  
220 Devanand DP (2009) The impact of anxiety on conversion from mild cognitive impairment  
221 to Alzheimer's disease. *International Journal of Geriatric Psychiatry* **24**, 1335-1342.
- 222 [15] Deniz K, Ho CCG, Malphrus KG, Reddy JS, Nguyen T, Carnwath TP, Crook JE, Lucas  
223 JA, Graff-Radford NR, Carrasquillo MM, Ertekin-Taner N (2021) Plasma Biomarkers of  
224 Alzheimer's Disease in African Americans. *J Alzheimers Dis* **79**, 323-334.

225

226




227

Stage	CN		MCI		AD	
	Anxious (n=16)	Non- Anxious (n=87)	Anxious (n=25)	Non- Anxious (n=28)	Anxious (n=10)	Non- Anxious (n=31)
<b>Demographic</b>						
<b>Age, years (SD)</b>	67.94 (5.38)	72.26 (7.81)	75.91 (10.18)	77.53 (8.98)	78.52 (10.95)	82.94 (9.61)
<b>% Women</b>	75.00	65.52	72.00	85.71	80.00	58.06
<b>%Non-Hispanic White</b>	87.50	87.36	92.00	78.57	40.00	83.87
<b>Education, years (SD)</b>	14.88 (4.15)	17.17 (2.36)	16.84 (2.34)	16.07 (3.39)	12.90 (5.71)	12.83 (5.24)
<b>% ApoE4 carrier</b>	25.00	26.44	40.00	25.00	50.00	25.81

**Table 1.** Demographic and psychometric characteristics of the study population.

228



229

Test/Group	AD-anxiety	AD+anxiety	p-value
<b>MMSE</b>	20.77 (5.56)	21.22 (3.19)	0.8190
<b>Animals</b>	11.90 (3.85)	10.78 (4.52)	0.4687
<b>Vegetables</b>	7.79 (2.92)	7.33 (2.12)	0.6652
<b>Trails A</b>	72.19 (39.75)	76.63 (42.41)	0.7769

**Table 2.** Comparisons of psychometric instrument scores between anxious and non-anxious AD participants (values reported as test scores +/- SD).

230

231